In February 2024, Innovative Health, LLC filed a patent infringement action against Vein360, LLC in the U.S. District Court for the Southern District of Ohio, asserting U.S. Patent No. 11,896,730 against a suite of Vein360’s reprocessed intravascular imaging catheters — including multiple Eagle Eye Platinum and Visions PV product lines. The case, assigned to Chief Judge Douglas R. Cole under Case No. 1:24-cv-00068, closed in just 83 days, suggesting an early resolution without full trial proceedings.

This dispute sits at the intersection of medical device reprocessing and patent exclusivity — a commercially significant battleground as reprocessors challenge OEM market positions. IP professionals in the cardiovascular and medical device sectors should pay close attention: the short case duration and the specificity of the asserted patent’s claims signal important strategic considerations for both patent holders enforcing reprocessing rights and competitors navigating freedom-to-operate in the single-use device reprocessing space.

Case Overview

The Parties

The Patent at Issue

U.S. Patent No. 11,896,730 (Application No. US18/491553) covers technology related to the reprocessing of single-use intravascular imaging catheters — specifically devices like intravascular ultrasound (IVUS) catheters used during cardiovascular procedures. The patent’s claims likely encompass methods and/or apparatus for cleaning, sterilizing, and restoring functional integrity to catheters originally labeled for single use, enabling their safe redeployment in clinical settings. This technology directly competes with OEM original catheter sales by creating a validated secondary market for refurbished high-value imaging devices.

• • US11896730B1

Legal Representation

Plaintiff Counsel: UB Greensfelder, LLP (lead: Rachael Leigh Rodman)

Litigation Timeline & Procedural History

The case was filed on February 13, 2024 in the U.S. District Court for the Southern District of Ohio — a first-instance district court venue. Ohio’s Southern District is a relatively active forum for commercial and IP disputes in the Midwest, and Chief Judge Douglas R. Cole presided over this matter. The choice of venue likely reflects Vein360’s business presence or commercial activities in Ohio, which established personal jurisdiction and proper venue for Innovative Health’s infringement claims.

The case closed on May 6, 2024, just 83 days after filing — an unusually short duration for patent infringement litigation, which typically spans 18 to 36 months through trial. This accelerated closure strongly suggests the matter was resolved through early settlement, a consent judgment, or a voluntary dismissal, rather than through claim construction, summary judgment, or trial on the merits. No formal verdict or basis of termination is recorded in the available case data, which is consistent with a confidential settlement or negotiated resolution reached before substantive motion practice concluded. IP practitioners should note that the absence of a public verdict does not diminish the strategic significance of the assertions made or the commercial leverage the patent provided.

The Verdict & Legal Analysis

Outcome

No formal verdict was entered in this matter. The case closed on May 6, 2024, approximately 83 days after filing, with no recorded basis of termination, damages award, or injunctive relief order in the publicly available case data. The rapid closure is most consistent with a private settlement or voluntary dismissal, meaning the court did not adjudicate the merits of the infringement claims asserted under U.S. Patent No. 11,896,730.

Verdict Cause Analysis

Although no formal verdict was issued, the infringement action was premised on the following legal and factual grounds:

• Innovative Health alleged that Vein360’s reprocessed Eagle Eye Platinum Catheter, Eagle Eye Platinum ST Catheter, Visions PV .014P RX Catheter, and Visions PV .035 Catheter each infringed one or more claims of U.S. Patent No. 11,896,730.
• The asserted patent, which issued as a first-instance grant (Application No. US18/491553), covers reprocessing methods and/or apparatus for intravascular imaging catheters, providing a novel basis for IP enforcement in the medical device reprocessing industry.
• Vein360’s commercial reprocessing and resale of these catheter models formed the accused acts of infringement, with the products specifically identified by name in the pleadings — a signal that claim charts and product mapping were likely well-developed at filing.
• The infringement action category indicates Innovative Health sought both damages for past infringement and, potentially, injunctive relief to prevent Vein360’s continued commercialization of the accused catheter products.

Legal Significance

1. 1. The rapid 83-day resolution of a patent infringement case involving a recently issued utility patent suggests the patent’s claims were considered credible and commercially threatening enough to prompt early resolution, underscoring the enforcement leverage that freshly issued medical device patents can carry.
2. 2. Because no claim construction order or summary judgment ruling was issued, there is no public record narrowing the scope of US11896730B1’s claims — meaning the patent retains its full presumptive scope and remains a live FTO risk for any company active in intravascular catheter reprocessing.
3. 3. This case signals that the medical device reprocessing sector is entering a period of active patent enforcement, and competitors holding or seeking to commercialize reprocessed single-use imaging catheters should anticipate similar infringement actions from patent holders with portfolios in this space.

Strategic Takeaways

For Patent Attorneys:

• When filing patent infringement actions in the medical device reprocessing space, specifically naming accused products in the complaint — as Innovative Health did with four distinct catheter SKUs — strengthens the credibility of the pleading and supports a preliminary injunction posture if pursued.
• The 83-day closure without a public ruling preserves the asserted patent’s full claim scope, which is a favorable outcome for the patent holder; counsel should structure settlements to include broad product coverage and future-product language to prevent design-around workarounds.
• Practitioners advising reprocessing companies should conduct pre-launch FTO analyses specifically targeting recently issued patents (within 2-3 years of issuance) in the FDA 510(k) cleared device reprocessing category, as this case demonstrates that enforcement can follow quickly after grant.
• For defendant-side counsel, the absence of any recorded defendant agent or law firm in this case may indicate Vein360 was initially unrepresented or slow to engage counsel — early and aggressive representation is critical in patent cases given the default judgment risk.

For IP Professionals:

• In-house IP teams at medical device reprocessors should immediately map their current product lines against US11896730B1 and related family members, as the patent’s enforcement against four distinct catheter products signals broad claim coverage across multiple intravascular imaging catheter types.
• Portfolio managers monitoring the reprocessed medical device space should flag Innovative Health, LLC as an active patent enforcer and implement ongoing watch alerts for any continuation or divisional applications stemming from Application No. US18/491553.

For R&D Teams:

• R&D teams developing reprocessed intravascular imaging catheters — particularly those working with IVUS platforms similar to the Volcano/Philips Eagle Eye or Visions PV product lines — should commission an FTO clearance study against US11896730B1 before initiating any clinical validation or 510(k) submission activities.
• Engineering teams exploring design-around options should analyze the independent claims of US11896730B1 for process-step limitations or apparatus elements that may be circumvented through alternative reprocessing methods, sterilization sequences, or catheter restoration techniques that do not read on the patent’s claim language.